基于美国医学AI智能体OpenEvidence以一年四轮融资、120亿美元估值的亮眼表现,全球资本市场掀起医疗AI热潮,在政策引导、技术突破与市场需求的三重驱动下,中国AI医疗行业正告别单一诊疗场景的探索,迈入以循证医学为核心、覆盖全产业链的多元化创新新阶段。从互联网医疗巨头到专注垂直领域的科技公司,纷纷以“循证医学”为核心,结合本土医疗场景特点,推出了各具特色的AI产品与解决方案,形成了覆盖D端...
Source Link基于美国医学AI智能体OpenEvidence以一年四轮融资、120亿美元估值的亮眼表现,全球资本市场掀起医疗AI热潮,在政策引导、技术突破与市场需求的三重驱动下,中国AI医疗行业正告别单一诊疗场景的探索,迈入以循证医学为核心、覆盖全产业链的多元化创新新阶段。从互联网医疗巨头到专注垂直领域的科技公司,纷纷以“循证医学”为核心,结合本土医疗场景特点,推出了各具特色的AI产品与解决方案,形成了覆盖D端...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.